SCHEMBL3113385

SCHEMBL3113385

Cc1n[nH]c2nccc(Oc3ccc(N(C(=O)C4(C(N)=O)CC4)c4ccc(F)cc4)c(Cl)c3)c12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 18/20 0.40
MERTK Q12866 11/20 0.40
MET P08581 10/20 0.40
TYRO3 Q06418 3/20 0.35
EGFR P00533 2/20 0.35
RET P07949 2/20 0.35
KIT P10721 2/20 0.35
FGFR1 P11362 2/20 0.35
FLT1 P17948 2/20 0.35
FLT4 P35916 2/20 0.35
KDR P35968 2/20 0.35
AURKA O14965 1/20 0.35
RIPK2 O43353 1/20 0.35
ABCB11 O95342 1/20 0.35
ABL1 P00519 1/20 0.35
ERBB2 P04626 1/20 0.35
NTRK1 P04629 1/20 0.35
LCK P06239 1/20 0.35
PGR P06401 1/20 0.35
LYN P07948 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3102184 0.92 AXL (0.38) AXLMERTKMETTYRO3EGFR
SCHEMBL3101269 0.92 AXL (0.37) AXLMERTKMETTYRO3EGFR
SCHEMBL3099969 0.90 MET (0.36) AXLMERTKMETTYRO3RET
SCHEMBL3108895 0.90 AXL (0.40) AXLMERTKMETTYRO3EGFR
SCHEMBL3111368 0.87 AXL (0.36) AXLMERTKMETTYRO3EGFR
SCHEMBL3108923 0.86 AXL (0.40) AXLMERTKMETTYRO3EGFR
SCHEMBL3097595 0.86 MET (0.34) AXLMERTKMETTYRO3RET
SCHEMBL3104646 0.86 AXL (0.35) AXLMERTKMETTYRO3EGFR
SCHEMBL3112277 0.85 AXL (0.37) AXLMERTKMETTYRO3EGFR
SCHEMBL3101845 0.83 MET (0.42) AXLMERTKMETTYRO3RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723330-B2 Heterobicyclic pyrazole compounds and methods of use ARRAY BIOPHARMA INC. (US) 2010-05-25 US claimed
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ROR1, CYP11B1, CYP11B2 AXL 117/4885MERTK 285/4885MET 357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.